Recent News

• 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.10.2025 - HCW Global Healthcare Conference
• 09.02.2025 - Christopher Raymond
• 08.21.2025 - HCW @ Home with Tyra Biosciences, Inc.
• 08.21.2025 - Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
• 08.20.2025 - Tyra Biosciences Announces Participation at Upcoming Investor Events
• 08.14.2025 - Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
• 07.25.2025 - Fireside Chat on Achondroplasia and Growth Disorders with Tyra Biosciences
• 07.21.2025 - Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
• 07.08.2025 - Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Recent Filings

• 08.22.2025 - 8-K Current report
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 4 Statement of changes in beneficial ownership of securities